1 day Ago By ABMN Staff
Quest Diagnostics Incorporated ( NYSE:DGX – Get Free Report ) was the target of a large decline in short interest in August. As of August 31st, there was short interest totalling 2,550,000 shares, a decline of 8.6% from the August 15th total of 2,790,000 shares.
Currently, 2.3% of the shares of the company are sold short. Based on an average daily trading volume, of 844,400 shares, the short-interest ratio is presently 3.
0 days. Insider Activity at Quest Diagnostics In other news, SVP Karthik Kuppusamy sold 1,990 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $153.
26, for a total transaction of $304,987.40. Following the sale, the senior vice president now directly owns 11,459 shares in the company, valued at $1,756,206.
34. The sale was disclosed in a document filed with the SEC, which is available at this link . In related news, SVP Karthik Kuppusamy sold 1,990 shares of the business’s stock in a transaction dated Wednesday, August 28th.
The stock was sold at an average price of $153.26, for a total transaction of $304,987.40.
Following the completion of the transaction, the senior vice president now directly owns 11,459 shares in the company, valued at $1,756,206.34. The transaction was disclosed in a document filed with the SEC, which is available through this link .
Also, SVP Mark E. Delaney sold 420 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.
08, for a total value of $60,093.60. Following the completion of the sale, the senior vice president now directly owns 5,019 shares in the company, valued at approximately $718,118.
52. The disclosure for this sale can be found here . 0.
79% of the stock is owned by company insiders. Institutional Inflows and Outflows Institutional investors have recently made changes to their positions in the company. Rothschild Investment LLC bought a new position in Quest Diagnostics in the second quarter worth $26,000.
Spartan Planning & Wealth Management purchased a new stake in shares of Quest Diagnostics in the 4th quarter worth about $31,000. Innealta Capital LLC bought a new position in shares of Quest Diagnostics in the 2nd quarter worth about $31,000. Larson Financial Group LLC lifted its position in Quest Diagnostics by 77.
5% during the 2nd quarter. Larson Financial Group LLC now owns 229 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 100 shares during the period. Finally, Riverview Trust Co bought a new stake in Quest Diagnostics during the first quarter worth about $33,000.
Institutional investors own 88.06% of the company’s stock. Quest Diagnostics Price Performance Quest Diagnostics ( NYSE:DGX – Get Free Report ) last posted its earnings results on Tuesday, July 23rd.
The medical research company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.31 by $0.
04. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.
35%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.
39 billion. During the same period last year, the company posted $2.30 EPS.
The company’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, equities research analysts forecast that Quest Diagnostics will post 8.
89 earnings per share for the current year. Quest Diagnostics Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 21st. Shareholders of record on Friday, October 4th will be given a dividend of $0.
75 per share. The ex-dividend date of this dividend is Friday, October 4th. This represents a $3.
00 annualized dividend and a yield of 1.93%. Quest Diagnostics’s payout ratio is 40.
38%. Analyst Ratings Changes A number of equities analysts recently weighed in on DGX shares. StockNews.
com raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 23rd. Evercore ISI began coverage on shares of Quest Diagnostics in a report on Wednesday, August 28th. They issued an “in-line” rating and a $165.
00 price objective for the company. Piper Sandler increased their target price on shares of Quest Diagnostics from $145.00 to $150.
00 and gave the company a “neutral” rating in a report on Monday, July 29th. Citigroup upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $145.00 to $165.
00 in a research report on Wednesday, July 10th. Finally, Truist Financial upped their price target on shares of Quest Diagnostics from $150.00 to $158.
00 and gave the company a “hold” rating in a research report on Monday, July 15th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.
com, the company has an average rating of “Hold” and an average price target of $154.33. Check Out Our Latest Research Report on DGX About Quest Diagnostics ( Get Free Report ) Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally.
The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. Featured Articles Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter .
.
